Exhaled air contains thousands of volatile organic compounds (VOCs) of which the composition varies depending on disease status. Moreover, bacteria in the lungs excrete VOCs which generate unique VOC patterns allowing identification of bacterial species including antibiotic-resistant strains.
The academic group of the founder of XAir has developed a proprietary discovery platform (XVOC) which allows the identification of VOC sets that correlate with a number of diseases with high sensitivity (>90%) and specificity (>90%).
XAir is developing assays for progression of disease and response to therapy for the following diseases: (1) Crohn’s disease, (2) Ulcerative Colitis, and (3) bacterial lung infections in Chronic Obstructive Pulmonary Disease (COPD) and Ventilator Associated Pneumonia (VAP). XAir is in the final stages of large validation studies with the aim to introduce assays to physicians within the next few years.